On September 7, 2023, the new indication for the injectable drug Telitacicept developed by RemeGen was accepted by the Center for Drug Evaluation (CDE) for the treatment of rheumatoid arthritis (RA).

This article summarized the latest R&D progress of Idoxuridine, the Mechanism of Action for Idoxuridine, and the drug target R&D trends for Idoxuridine.

On September 6, 2023, Shanghai Yingli Pharmaceutical announced that its PI3Kδ inhibitor, Linperlisib, has been accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China for a new indication filing.

Adenosine receptors play a crucial role in various physiological processes within the human body.

ImmunoGen, Inc. is a biopharmaceutical company that was founded in 1981 and is based in Massachusetts, United States.

Genentech, a member of the Roche, announced that the U.S. FDA has accepted the company's BLA for the novel complement C5 monoclonal antibody Crovalimab for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).

This article summarized the latest R&D progress of Flurandrenolide, the Mechanism of Action for Flurandrenolide, and the drug target R&D trends for Flurandrenolide.

Korean biotech firm Alteogen Inc. has publicized the findings of their most recent Tergase® clinical study, wherein no occurrence of ADA (inclusive of neutralizing antibodies) was found.

Horizon Therapeutics Plc is a pharmaceutical organization based in Dublin, Ireland. It was founded in 2008 and has since been actively involved in the field of biomedicine.

Arcturus Therapeutics Holdings have revealed today that EMA has officially confirmed the marketing authorization application for ARCT-154.

ALK (Anaplastic Lymphoma Kinase) is a receptor tyrosine kinase that plays a crucial role in various physiological processes in the human body.

This article summarized the latest R&D progress of Succinylcholine Chloride, the Mechanism of Action for Succinylcholine Chloride, and the drug target R&D trends for Succinylcholine Chloride.